Larvol Delta - The-Use-of-Cytomegalovirus-Cell-Mediated-Immunity-to-Optimize-the-Duration-of-Letermovir-Prophylaxis-in-Hematopoietic-Cell-Transplant-Recipients

Prevymis (letermovir) - Merck (MSD)

http://clinicaltrials.gov/ct2/show/NCT06639854

Jun 16, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next